Get the Stockscreener App
77.49
4.82%
3.56
After Hours:
75.61
-1.88
-2.43%
Verona Pharma Plc Adr stock is traded at $77.49, with a volume of 1.46M.
It is up +4.82% in the last 24 hours and up +5.84% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$73.93
Open:
$74
24h Volume:
1.46M
Relative Volume:
1.08
Market Cap:
$52.78B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
-38.74
EPS:
-2
Net Cash Flow:
$-103.81M
1W Performance:
+6.60%
1M Performance:
+5.84%
6M Performance:
+95.53%
1Y Performance:
+553.92%
1-Day Range:
$73.14
$77.98
1-Week Range:
$71.00
$77.98
52-Week Range:
$11.39
$77.98
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Compare VRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | TD Cowen | Buy |
| Apr-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Oct-03-24 | Initiated | Wells Fargo | Overweight |
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Verona Pharma Announces June 2025 Investor Conference Participation - GlobeNewswire Inc.
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
TD Cowen starts Verona Pharma stock at Buy, sets $100 target - Investing.com
Verona Pharma Shareholders Approve All Proposals at AGM By Investing.com - Investing.com South Africa
Verona Pharma Shareholders Approve All Proposals at AGM - Investing.com
A significant driver of top-line growth: Verona Pharma Plc ADR (VRNA) - Sete News
Is Astrazeneca plc ADR (AZN) positioned for future growth? - Sete News
Verona Pharma Plc ADR [VRNA] Records 50-Day SMA of $62.73 - knoxdaily.com
Tencent Music Entertainment Group ADR [TME] Officer makes an insider purchase of 1,036,363 shares worth 14.87 million. – Knox Daily - knoxdaily.com
TAL Education Group ADR [TAL] Officer makes an insider purchase of 24,041 shares worth 0.28 million. - knoxdaily.com
Ratios Uncovered: Breaking Down Verona Pharma Plc ADR (VRNA)’s Trailing Twelve Months Metrics - DWinneX
Verona Pharma Plc ADR (VRNA) is a good investment, but the stock may be overvalued - uspostnews.com
What is the investor’s view on Marriott Vacations Worldwide Corp (VAC)? - uspostnews.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Financial Health Report: Alamos Gold Inc (AGI)’s Ratios Tell a Tale - DWinneX
Cantor Fitzgerald sets $80 target on Verona Pharma stock By Investing.com - Investing.com South Africa
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit undervalued - uspostnews.com
Verona Pharma Plc ADR [VRNA] Rickard Kathleen A. sells 79,264 Shares for $0.66 million - knoxdaily.com
Verona Pharma Plc ADR [VRNA] Chief Medical Officer makes an insider purchase of 79,264 shares worth 0.66 million. - knoxdaily.com
Verona Pharma secures $450 million credit facility on better terms By Investing.com - Investing.com South Africa
Verona Pharma secures $450 million credit facility on better terms - Investing.com
Xeris Biopharma reshuffles board, appoints new director - Investing.com
The growth track for Cracker Barrel Old Country Store Inc (CBRL) has changed recently - SETE News
Verona Pharma Plc ADR (NASDAQ: VRNA) Up 298.80% This Year: What Is Going To Happen Next - Stocks Register
Verona Pharma’s chief medical officer sells shares worth $661,941 - Investing.com India
Verona Pharma’s chief medical officer sells shares worth $661,941 By Investing.com - Investing.com South Africa
Keeping an Eye on Gilead Sciences, Inc (GILD) After Insider Trading Activity - Knox Daily
McEwen Mining Inc (MUX) Becoming More Attractive for Investors - Knox Daily
Morgan Stanley Upgrades Solaredge Technologies Inc (SEDG) to an Equal-weight from an Underweight - Knox Daily
Verona Pharma at Leerink Global Healthcare: Eutuvera’s Promising Launch By Investing.com - Investing.com UK
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts By Investing.com - Investing.com South Africa
Verona Pharma stock surges as Q4 revenue soars past estimates - Investing.com India
Verona Pharma stock surges as Q4 revenue soars past estimates By Investing.com - Investing.com Canada
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts - Investing.com
Verona Pharma plc (NASDAQ:VRNA) Q4 2024 Earnings Call Transcript - MSN
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):